Stéphanie Verbeke

479 total citations
12 papers, 369 citations indexed

About

Stéphanie Verbeke is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stéphanie Verbeke has authored 12 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stéphanie Verbeke's work include Sarcoma Diagnosis and Treatment (4 papers), Nerve injury and regeneration (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). Stéphanie Verbeke is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Nerve injury and regeneration (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). Stéphanie Verbeke collaborates with scholars based in France, Singapore and United States. Stéphanie Verbeke's co-authors include Éric Adriaenssens, Samuel Meignan, Emmanuelle Germain, Hubert Hondermarck, Xuefen Le Bourhis, Elsa Vanhecke, Victor Nurcombe, Nathalie Berteaux, Antoîne Italiano and Audrey Laroche‐Clary and has published in prestigious journals such as Cancer Research, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Stéphanie Verbeke

12 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphanie Verbeke France 10 179 123 93 72 55 12 369
Rodrigue Romon France 6 251 1.4× 166 1.3× 158 1.7× 52 0.7× 85 1.5× 6 523
Patricia Fernández‐Nogueira Spain 9 183 1.0× 112 0.9× 108 1.2× 34 0.5× 50 0.9× 13 357
Frances Chow United States 10 135 0.8× 135 1.1× 49 0.5× 58 0.8× 53 1.0× 32 469
Minhui Xu China 13 150 0.8× 61 0.5× 55 0.6× 77 1.1× 60 1.1× 35 371
Fabiana Lubieniecki Argentina 14 362 2.0× 101 0.8× 126 1.4× 34 0.5× 23 0.4× 53 651
Christopher A. Kerfoot United States 10 196 1.1× 120 1.0× 48 0.5× 38 0.5× 56 1.0× 16 462
Tetsushi Hayakawa Japan 12 113 0.6× 142 1.2× 64 0.7× 95 1.3× 41 0.7× 52 448
Verónica Rivas Spain 11 367 2.1× 101 0.8× 73 0.8× 23 0.3× 51 0.9× 19 473
Maiko Yamaji United Kingdom 8 284 1.6× 110 0.9× 113 1.2× 29 0.4× 67 1.2× 9 428
Luisa Milazzo Italy 10 170 0.9× 65 0.5× 42 0.5× 65 0.9× 55 1.0× 18 500

Countries citing papers authored by Stéphanie Verbeke

Since Specialization
Citations

This map shows the geographic impact of Stéphanie Verbeke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Verbeke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Verbeke more than expected).

Fields of papers citing papers by Stéphanie Verbeke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Verbeke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Verbeke. The network helps show where Stéphanie Verbeke may publish in the future.

Co-authorship network of co-authors of Stéphanie Verbeke

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Verbeke. A scholar is included among the top collaborators of Stéphanie Verbeke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Verbeke. Stéphanie Verbeke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Verbeke, Stéphanie, et al.. (2024). Dual inhibition of BET and EP300 has antitumor activity in undifferentiated pleomorphic sarcomas and synergizes with ferroptosis induction. Translational Oncology. 52. 102236–102236. 2 indexed citations
2.
Verbeke, Stéphanie, Jean‐Philippe Guégan, Laura Leroy, et al.. (2023). Antitumor Effects of PRMT5 Inhibition in Sarcomas. Cancer Research Communications. 3(11). 2211–2220. 1 indexed citations
3.
S, Roy, Audrey Laroche‐Clary, Stéphanie Verbeke, Marie‐Alix Derieppe, & Antoîne Italiano. (2020). MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers. 12(8). 2253–2253. 11 indexed citations
4.
Toulmonde, Maud, Carlo Lucchesi, Stéphanie Verbeke, et al.. (2020). High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 62. 103131–103131. 40 indexed citations
5.
Laroche‐Clary, Audrey, Vanessa Chaire, Stéphanie Verbeke, et al.. (2020). ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. Scientific Reports. 10(1). 7488–7488. 20 indexed citations
6.
Laroche‐Clary, Audrey, Carlo Lucchesi, Christophe Rey, et al.. (2018). CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Annals of Oncology. 29(4). 1023–1029. 14 indexed citations
7.
Verbeke, Stéphanie, Élodie Richard, Benoı̂t Rousseau, et al.. (2014). Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells. Breast Cancer Research. 16(6). 126–126. 12 indexed citations
8.
Vindrieux, David, Arnaud Augert, Christophe A. Girard, et al.. (2013). PLA2R1 Mediates Tumor Suppression by Activating JAK2. Cancer Research. 73(20). 6334–6345. 52 indexed citations
9.
Lallet-Daher, Hélène, Clotilde Wiel, Delphine Gitenay, et al.. (2013). Potassium Channel KCNA1 Modulates Oncogene-Induced Senescence and Transformation. Cancer Research. 73(16). 5253–5265. 42 indexed citations
10.
Verbeke, Stéphanie, et al.. (2013). Extracellular cleavage of the p75 neurotrophin receptor is implicated in its pro‐survival effect in breast cancer cells. FEBS Letters. 587(16). 2591–2596. 21 indexed citations
11.
Vanhecke, Elsa, Éric Adriaenssens, Stéphanie Verbeke, et al.. (2011). Brain-Derived Neurotrophic Factor and Neurotrophin-4/5 Are Expressed in Breast Cancer and Can Be Targeted to Inhibit Tumor Cell Survival. Clinical Cancer Research. 17(7). 1741–1752. 101 indexed citations
12.
Verbeke, Stéphanie, Samuel Meignan, Chann Lagadec, et al.. (2010). Overexpression of p75NTR increases survival of breast cancer cells through p21waf1. Cellular Signalling. 22(12). 1864–1873. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rodrigue Romon Breakdown of academic impact, for papers by Patricia Fernández‐Nogueira Breakdown of academic impact, for papers by Frances Chow Breakdown of academic impact, for papers by Minhui Xu Breakdown of academic impact, for papers by Fabiana Lubieniecki Breakdown of academic impact, for papers by Christopher A. Kerfoot Breakdown of academic impact, for papers by Tetsushi Hayakawa Breakdown of academic impact, for papers by Verónica Rivas Breakdown of academic impact, for papers by Maiko Yamaji Breakdown of academic impact, for papers by Luisa Milazzo
Rankless by CCL
2026